Xeptiva Therapeutics Advances Therapeutic Vaccines for Chronic Inflammatory Conditions in Companion Animals

Xeptiva develops therapeutic vaccines for chronic pet diseases

Uruguayan biotechnology company Xeptiva Therapeutics is developing a portfolio of therapeutic vaccines designed to address chronic inflammatory and age-associated conditions in companion animals.

Founded in 2021 following more than a decade of research into neuroinflammation, the company currently lists five programmes across canine, feline and equine chronic disease.

Its leading programmes are:

A different model for chronic pain

Xep01 is being developed as a therapeutic vaccine for chronic pain associated with canine osteoarthritis.

Rather than repeatedly administering a conventional analgesic, the vaccine is designed to stimulate the animal’s immune system to produce antibodies against biological targets involved in pain and inflammation.

The underlying technology is based on a recombinant fusion immunogen targeting nerve growth factor (NGF) and Substance P, two biological pathways associated with pain signalling.

A 2026 peer-reviewed paper involving Xeptiva researchers reported that vaccination with the recombinant immunogen generated antibodies against NGF and Substance P in several animal models, including dogs. Antibodies generated in vaccinated dogs also neutralised the biological activity of NGF and Substance P in cell-based experiments.

These findings demonstrate biological activity but do not by themselves establish clinical efficacy or regulatory approval.

Xep01 clinical development

Xeptiva’s clinical programme is designed to test Xep01 in dogs with osteoarthritis-associated chronic pain. The company’s published trial information describes a controlled study involving dogs with moderate chronic pain, with Xep01 compared with placebo.

The protocol described by the company includes:

• Veterinary screening

• Clinical follow-up

• Repeated treatment

• Blood sampling

• Pain and clinical assessments

• Mobility and wellbeing evaluation

The company’s current website indicates that recruitment for the Xep01 clinical trial is closed.

Xep02: canine atopic dermatitis

The second leading programme, Xep02, targets chronic canine atopic dermatitis. The therapeutic concept is similarly based on immunotherapy rather than continuous daily pharmacological suppression.

Xeptiva states that earlier studies demonstrated reductions in itching and inflammation and a potential reduction in the need for long-term medication. A pilot safety study in dogs was also reported by the company.

The current Xep02 clinical-trial page lists recruitment as closed.

Why therapeutic vaccines are strategically interesting

Chronic companion-animal diseases create a different commercial model from acute veterinary treatment. Conditions such as:

• Osteoarthritis

• Chronic dermatitis

• Chronic pain

• Obesity

• Age-related inflammatory disease

often require long-term management.

That creates a large recurring medication burden for owners and a substantial long-term treatment market for animal-health companies.

Therapeutic vaccination potentially changes the treatment paradigm:

Daily / repeated medication → immune-mediated long-duration intervention

If demonstrated clinically, this could alter treatment frequency, compliance and veterinary economics.

Scientific and commercial risk

The concept is innovative but requires a high evidence threshold. Critical development questions include:

• Duration of therapeutic effect

• Magnitude of pain reduction

• Objective mobility outcomes

• Safety after repeated administration

• Immunogenicity

• Dose optimisation

• Patient selection

• Comparison with established therapies

• Long-term adverse events

• Regulatory pathway

The most important transition is therefore from promising immunological activity to reproducible clinical benefit in appropriately controlled veterinary trials.

Strategic / Analyst View

Xeptiva represents a broader movement in animal health toward biological and immune-mediated treatments for chronic disease.

The company’s approach could potentially compete with repeated-use pharmacological treatments by changing the frequency and mechanism of intervention.

For the animal-health industry, the opportunity is strategically important because chronic pet disease is moving toward a healthspan-management model, where owners increasingly seek long-duration solutions rather than repeated symptomatic treatment.

The 2026 scientific publication strengthens the mechanistic evidence base, but commercial value will ultimately depend on controlled clinical outcomes and regulatory approval.

Bottom line

Xeptiva is developing an unconventional therapeutic-vaccine platform targeting chronic companion-animal conditions, with canine osteoarthritis and atopic dermatitis currently the most advanced programmes. The key 2026 development milestone is the transition from preclinical and pilot evidence toward controlled clinical validation.